BR112018075395A2 - combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas - Google Patents

combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas

Info

Publication number
BR112018075395A2
BR112018075395A2 BR112018075395-5A BR112018075395A BR112018075395A2 BR 112018075395 A2 BR112018075395 A2 BR 112018075395A2 BR 112018075395 A BR112018075395 A BR 112018075395A BR 112018075395 A2 BR112018075395 A2 BR 112018075395A2
Authority
BR
Brazil
Prior art keywords
chronic
diabetes
nutra
bioenergetic
epigenetic
Prior art date
Application number
BR112018075395-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Astudillo De La Vega Horacio
Original Assignee
Astudillo De La Vega Horacio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astudillo De La Vega Horacio filed Critical Astudillo De La Vega Horacio
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of BR112018075395A2 publication Critical patent/BR112018075395A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112018075395-5A 2015-06-08 2017-06-08 combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas BR112018075395A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
US15/176,422 2016-06-08
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
MXMX/A/2017/007448 2017-06-07
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (1)

Publication Number Publication Date
BR112018075395A2 true BR112018075395A2 (pt) 2019-04-02

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075395-5A BR112018075395A2 (pt) 2015-06-08 2017-06-08 combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US20100209382A1 (en) * 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
WO2008143182A1 (ja) * 2007-05-17 2008-11-27 Kaneka Corporation 甘草ポリフェノールを含有する組成物
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
RU2017129378A (ru) * 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей

Also Published As

Publication number Publication date
CA3027048A1 (en) 2017-12-14
JP2019521184A (ja) 2019-07-25
CN109890369A (zh) 2019-06-14
CN109890369B (zh) 2022-04-29
RU2018147077A3 (enExample) 2020-09-21
MX365886B (es) 2019-06-19
MX2017007448A (es) 2018-09-10
ES2988151T3 (es) 2024-11-19
US20160354331A1 (en) 2016-12-08
RU2018147077A (ru) 2020-07-10
US10285963B2 (en) 2019-05-14
RU2749950C2 (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
Martínez-Ceron et al. Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea
Sulaiman et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy
Jiang et al. Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats
Sun et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity
Pereira et al. OPA 1 deficiency promotes secretion of FGF 21 from muscle that prevents obesity and insulin resistance
Rochette et al. Diabetes, oxidative stress and therapeutic strategies
Yan et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases
Li et al. Sestrin 2 induces autophagy and attenuates insulin resistance by regulating AMPK signaling in C2C12 myotubes
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
Su et al. Mitophagy in hepatic insulin resistance: therapeutic potential and concerns
Argilés et al. Muscle wasting in cancer: the role of mitochondria
Zhabyeyev et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload
Hu et al. Metformin and berberine prevent olanzapine-induced weight gain in rats
Tang et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase
Bezerra et al. Caffeic acid phenethyl ester reduces the activation of the nuclear factor κB pathway by high-fat diet-induced obesity in mice
Marette et al. Skeletal muscle glucose metabolism and inflammation in the development of the metabolic syndrome
Yang et al. Alpha-lipoic acid attenuates insulin resistance and improves glucose metabolism in high fat diet-fed mice
Totsch et al. Effects of a Standard American Diet and an anti‐inflammatory diet in male and female mice
Zheng et al. Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
Xu et al. Hypoglycemic and hypolipidemic effects of triterpenoid-enriched Jamun (Eugenia jambolana Lam.) fruit extract in streptozotocin-induced type 1 diabetic mice
Kusunoki et al. Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia
Rolland et al. Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review
Marin et al. Oestrogens as M odulators of N euronal Si gnalosomes and B rain L ipid H omeostasis R elated to P rotection A gainst N eurodegeneration
Bu et al. Blocking central galanin receptors attenuates insulin sensitivity in myocytes of diabetic trained rats

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.